GlassScriptPhysician profile
Cheiny Shiau
NPI 1477036895
$86,404.20
in general payments reported to CMS, 2019-2025
30 companies · $38K in 2025
The $38K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,492 · 2022: $4,258 · 2023: $12K · 2024: $30K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $27K · Travel and Lodging: $6,123 · Consulting Fee: $3,625 · Education: $308 · Honoraria: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,404.50 |
| Food and Beverage | $26,932.54 |
| Travel and Lodging | $6,123.41 |
| Consulting Fee | $3,625.00 |
| Education | $308.25 |
| Honoraria | $260.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32,803.17 | 2021-2025 | |
| Ucb, INC. | $14,546.64 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $14,510.51 | 2023-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $6,294.12 | 2023-2025 | Zoryve |
| Genzyme Corporation | $2,558.18 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,248.27 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $1,961.17 | 2021-2025 | |
| Amgen INC. | $1,793.97 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $1,569.99 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,511.40 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $1,299.32 | 2023-2024 | Vtama |
| Pfizer INC. | $1,205.86 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $759.68 | 2022-2025 | Winlevi, Absorica Ld, Odomzo |
| Janssen Biotech, INC. | $714.30 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $677.35 | 2021-2025 | Opzelura, Opzelura |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $507.25 | 2022-2025 | Adbry, Anzupgo |
| Journey Medical Corporation | $461.04 | 2022-2023 | |
| Verrica Pharmaceuticals INC. | $241.29 | 2023-2025 | Ycanth |
| Sanofi-Aventis U.S. LLC | $197.99 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $133.85 | 2024 | |
| Organon LLC | $119.78 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.18 | 2022-2023 | Spevigo |
| Fresenius Kabi USA, LLC | $55.64 | 2023 | Idacio |
| Argenx US, INC. | $33.25 | 2023 | Vyvgart |
| Janssen Scientific Affairs, LLC | $30.96 | 2025 | Tremfya |
| Botanix Sb INC | $25.03 | 2025 | Sofdra |
| Dermira, INC. | $24.88 | 2021 | |
| Lnhc, INC | $20.03 | 2025 | Zelsuvmi |
| Almirall LLC | $16.71 | 2021 | |
| Sandoz INC. | $14.39 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheiny Shiau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.